|
Non-profit venture philanthropy
|
| Location |
New York, New York, USA |
| Type |
501(c)(3) Non-Profit Organization |
| Website |
https://www.alzdiscovery.org/ |
| Focus Areas |
[Alzheimer's Disease](/diseases/alzheimers-disease) Drug Discovery, Diagnostics, Biomarkers |
| Founded |
1998 |
| Co-Founders |
Leonard A. Lauder, Howard Fillit, MD |
| CEO |
Isobel Coleman |
| Diagnostics Accelerator |
$150 million initiative |
The Alzheimer's Drug Discovery Foundation (ADDF) is a leading non-profit organization dedicated to accelerating the development of therapeutics for Alzheimer's disease and related dementias. Founded in 1998 by Leonard A. Lauder and Howard Fillit, MD, the ADDF employs a unique venture philanthropy model, making strategic investments in promising research programs and using returns to fund additional research.
Based in New York City, the ADDF has grown to become the leading non-profit funder of Alzheimer's drug discovery, having invested hundreds of millions of dollars in research worldwide. Unlike traditional charitable foundations that provide grants, the ADDF makes equity investments in biotechnology companies, providing both funding and strategic guidance to advance promising therapeutic approaches.
The organization's mission is to rapidly accelerate the development of effective drugs to prevent, treat, and cure Alzheimer's disease and related dementias. To achieve this mission, the ADDF focuses on supporting novel therapeutic approaches that target the biological mechanisms of aging rather than traditional amyloid-focused strategies.
¶ History and Foundation
¶ Founding and Early Years
The ADDF was founded in 1998 by Leonard A. Lauder, former chairman and CEO of Estée Lauder Companies, and Howard Fillit, MD, a physician-scientist specializing in geriatric medicine. The founding was motivated by the recognition that traditional research funding mechanisms were insufficient to drive the development of effective Alzheimer's therapies.
Leonard Lauder's involvement was deeply personal — his mother had died from Alzheimer's disease, and he was committed to finding a cure. Howard Fillit brought scientific expertise and a vision for applying venture capital principles to charitable research funding. Together, they created a new model for advancing Alzheimer's drug development.
¶ Growth and Evolution
Since its founding, the ADDF has evolved significantly:
- 1998: Founded as the Alzheimer's Drug Discovery Foundation
- 2000s: Built portfolio of early-stage investments in biotech companies
- 2010: Launched the Accelerating Medicines Partnership for Alzheimer's Disease (AMP-AD) with NIH
- 2015: Expanded focus to include diagnostics and biomarkers
- 2018: Launched the Diagnostics Accelerator program
- 2020: Supported development of numerous COVID-19 programs
- 2023: Launched $150 million phase of Diagnostics Accelerator
- 2024: Continued expansion of funding programs and portfolio
The ADDF has played a critical role in advancing the field of Alzheimer's drug discovery. While the pharmaceutical industry has largely focused on amyloid-targeting therapies, the ADDF has been a key funder of alternative approaches including neuroinflammation, mitochondrial dysfunction, synaptic health, and vascular biology.
The ADDF's venture philanthropy model distinguishes it from traditional charitable foundations. Key elements include:
- Equity Investments: The ADDF makes equity investments in biotech companies, not just grants
- Strategic Involvement: Provides guidance and connections beyond funding
- Reinvestment: Returns from investments are recycled into additional research
- Risk Tolerance: Accepts higher risk than traditional funders
- Portfolio Approach: Builds diverse portfolio of therapeutic approaches
The ADDF evaluates potential investments based on:
- Scientific Merit: Novel mechanism of action with strong preclinical data
- Team: Experienced management and scientific advisors
- Timeline: Realistic path to clinical development
- Market Opportunity: Significant unmet medical need
- Strategic Fit: Alignment with ADDF research priorities
This model has proven effective in advancing promising therapies that might not receive funding through traditional sources. By taking equity positions, the ADDF aligns its interests with company success while maintaining a charitable mission.
The core funding mechanism for therapeutic development:
- Seed Awards: Up to $150,000 for early-stage research
- Development Awards: Up to $600,000 for preclinical development
- Translation Awards: Up to $1 million for IND-enabling studies
The program specifically targets novel drug mechanisms related to the biology of aging:
- Epigenetics — Therapeutic approaches targeting epigenetic modifications that affect gene expression in the aging brain
- Inflammation — Neuroinflammation and immune modulation to address the inflammatory component of neurodegeneration
- Mitochondrial/Metabolic Function — Cellular energy metabolism and mitochondrial health
- Neuroprotection — Approaches to protect neurons from degeneration
- Proteostasis — Protein folding, aggregation, and clearance mechanisms
- Synaptic Activity — Synaptic function and plasticity
- Vascular Function — Cerebrovascular health and blood-brain barrier integrity
The ADDF explicitly does NOT fund:
- Amyloid-targeted approaches (monoclonal antibodies, aggregation inhibitors)
- Cholinesterase inhibitors
- Symptomatic treatments
- Generic drug repurposing without novel mechanism
This strategic focus reflects the ADDF's commitment to funding truly novel approaches that address underlying disease mechanisms rather than incremental improvements on failed strategies.
The Diagnostics Accelerator is a $150 million initiative launched in 2018 and significantly expanded in 2023 to advance novel biomarkers for early detection of Alzheimer's disease:
-
Blood-Based Biomarkers
- Development of blood tests for Alzheimer's detection
- Validation of biomarker panels
- Point-of-care testing development
- Integration with clinical practice
-
Digital Biomarkers
- Voice and speech analysis
- Movement and gait analysis
- Smartphone-based cognitive assessments
- Wearable device data
-
Novel Detection Methods
- CSF biomarkers
- Imaging agents
- Multi-omics approaches
- Computational diagnostics
-
Early Diagnostic Tools
- Pre-symptomatic detection
- Risk stratification
- Disease progression markers
- Treatment response biomarkers
- Blood Test Initiative: Funding development of blood-based tests that can detect Alzheimer's pathology before symptoms appear
- Digital Biomarker Program: Supporting development of technology-based tools for early detection
- Validation Studies: Funding large-scale validation of promising biomarkers
- Clinical Implementation: Working to move biomarkers from research to clinical use
The Diagnostics Accelerator represents the largest single investment in Alzheimer's diagnostics by a non-profit organization and has catalyzed significant progress in the field.
A joint program with the Harrington Discovery Institute providing funding and mentorship to accelerate breakthrough discoveries:
- Funding: Up to $400,000 over two years
- Mentorship: Access to drug development experts
- Strategic Guidance: Business development support
- Network Access: Connections to pharmaceutical partners
The program is designed to bridge the gap between academic research and pharmaceutical development, providing the resources and expertise needed to advance promising discoveries toward clinical testing.
A public-private partnership focused on identifying new therapeutic targets and biomarkers:
- National Institute on Aging (NIA)
- Pharmaceutical companies
- Academic research institutions
- Identify novel drug targets
- Develop biomarkers for patient selection
- Share data and resources
- Accelerate clinical trials
An award for excellence in Alzheimer's drug development:
- $500,000 prize recognizing significant advances
- Annual award to leading researchers
- Named in honor of ADDF board member
The 2026 prize was awarded to Randall J. Bateman, MD, for his work on novel clinical trial designs and biomarker development.
The ADDF has expanded to include frontotemporal dementia (FTD) as a focus area:
- Specific funding for FTD research
- Focus on novel therapeutic approaches
- Collaboration with FTD advocacy organizations
- Research on disease mechanisms unique to FTD
A research initiative focused on speech-based diagnostics:
- Development of speech analysis tools
- Voice biomarkers for early detection
- Integration with digital health platforms
- Clinical validation studies
The ADDF prioritizes research targeting the fundamental biology of aging that contributes to Alzheimer's disease:
Neuroinflammation has emerged as a critical driver of Alzheimer's pathogenesis. The ADDF funds research on:
- Microglial Activation: Understanding how immune cells in the brain contribute to neurodegeneration
- Inflammasome Inhibition: Targeting NLRP3 and other inflammasomes
- Cytokine Modulation: Developing anti-inflammatory therapies
- TREM2 Pathways: Supporting research on TREM2 variants and microglial function
The ADDF recognizes that epigenetic changes during aging contribute to cognitive decline:
- DNA Methylation: Understanding age-related methylation changes
- Histone Modifications: Targeting histone acetylation and deacetylation
- Non-coding RNAs: Exploring microRNA and long non-coding RNA involvement
- Reversibility: Developing drugs that can reverse harmful epigenetic changes
Mitochondrial dysfunction is a hallmark of aging and neurodegeneration:
- Bioenergetics: Supporting mitochondrial function
- Oxidative Stress: Protecting against reactive oxygen species
- Mitophagy: Enhancing clearance of damaged mitochondria
- Metabolic Pathways: Addressing brain energy metabolism
Synaptic loss correlates strongly with cognitive decline:
- Synaptic Plasticity: Supporting formation and maintenance of synapses
- Presynaptic Function: Understanding neurotransmitter release
- Postsynaptic Density: Targeting scaffold proteins and receptors
- Network Function: Maintaining neural circuit integrity
Cerebrovascular dysfunction contributes to Alzheimer's pathology:
- Blood-Brain Barrier: Protecting and repairing the BBB
- Cerebral Blood Flow: Maintaining adequate perfusion
- Pericyte Function: Supporting vascular stability
- Angiogenesis: Promoting healthy blood vessel formation
The ADDF has invested in numerous biotechnology companies developing Alzheimer's therapeutics. The portfolio spans multiple therapeutic modalities and mechanisms:
While the ADDF does not fund new amyloid-focused programs, its portfolio includes legacy investments:
- Acumen Pharmaceuticals — Anti-amyloid beta oligomer antibodies
- Alzheon — Amyloid aggregation inhibitors
- AC Immune — Anti-amyloid vaccines and antibodies
- Prothena — Amyloid-targeting antibodies
¶ Neuroprotection and Novel Mechanisms
- Axsome Therapeutics — Novel CNS therapeutics
- Cortexyme — Novel anti-infective approach targeting gingipains
- Anavex Life Sciences — Sigma-1 receptor agonists
- Athira Pharma — Neuroprotection via HGF/MET pathway
¶ Tau and Neurofibrillary Pathology
- Alnylam — RNAi therapeutics for tau
- Cerevel Therapeutics — Tau-targeted small molecules
- Pinteon Therapeutics — Tau-targeted immunotherapies
- Denali Therapeutics — LRRK2 inhibitors for neuroinflammation
- NodThera — NLRP3 inflammasome inhibitors
- Inmune Bio — Cytokine modulation
- Alector — Immune-glial targeting
- Lexeo Therapeutics — Gene therapy for Alzheimer's
- Life Biosciences — Multi-target approach
- Neumora Therapeutics — Precision neurology
- Isobel Coleman — Chief Executive Officer
- Howard Fillit, MD — Co-Founder and Chief Science Officer
- Leonard A. Lauder — Co-Founder and Co-Chairman (emeritus)
The ADDF is governed by a distinguished board including:
- Business leaders from pharmaceutical and finance industries
- Scientific advisors with expertise in neurodegeneration
- Patient advocates
The organization benefits from leading scientists in:
- Alzheimer's research
- Drug development
- Biomarker development
- Clinical trials
¶ Impact and Accomplishments
The ADDF's investments have contributed to:
- Novel Target Identification: Discovery of new therapeutic targets beyond amyloid
- Biomarker Development: Advancement of blood tests and digital biomarkers
- Company Formation: Creation of multiple biotech companies
- Clinical Trials: Advancement of novel therapies into clinical testing
The ADDF portfolio includes:
- Companies that have gone public
- Therapies in late-stage clinical trials
- Strategic acquisitions by pharmaceutical companies
- FDA approvals for portfolio companies
The ADDF has become a thought leader in:
- Alternative therapeutic approaches
- Diagnostics development
- Venture philanthropy in neurodegeneration
- Open science and data sharing
The ADDF operates as a 501(c)(3) non-profit organization with a unique financial model:
- Donations and contributions
- Investment returns
- Foundation grants
- Returns are reinvested in research
- Supports sustainable funding model
- Total funding: Hundreds of millions invested
- Diagnostics Accelerator: $150 million commitment
- Annual grant-making: Significant annual expenditures
¶ Collaboration and Partnerships
The ADDF collaborates with leading research institutions:
- University research centers
- Medical schools
- Teaching hospitals
- Research institutes
Working with major pharmaceutical companies:
- Drug development collaborations: Co-development agreements with pharmaceutical partners
- Clinical trial partnerships: Support for industry-sponsored trials
- Data sharing initiatives: Open science collaborations
- Target validation programs: Joint validation of novel targets
- Patient access programs: Supporting patient access to experimental therapies
The pharmaceutical partnerships are critical for advancing promising therapies through late-stage clinical development. While the ADDF excels at early-stage funding, pharmaceutical partners provide the resources and expertise needed for large-scale clinical trials and regulatory approval.
The ADDF works closely with government research agencies:
- National Institute on Aging (NIH): Largest single funder of Alzheimer's research, collaborating on AMP-AD and other initiatives
- European Union research programs: Participation in EU-funded dementia research
- National dementia strategies: Advisory role in national Alzheimer's plans
- FDA engagement: Dialogue with regulatory agencies on biomarker development and clinical trial design
The ADDF collaborates with other non-profit organizations:
- Alzheimer's Association: Joint initiatives on research and advocacy
- Alzheimer's Disease International: Global collaboration on awareness and research
- Patient advocacy organizations: Partnerships with disease-specific organizations
- Research foundations: Collaboration with other disease-focused foundations
- Family foundations: Partnerships with other family philanthropies
These partnerships amplify the impact of ADDF investments by combining resources, expertise, and networks across the Alzheimer's research ecosystem.
The Drug Development Program is the cornerstone of ADDF funding:
Discovery Stage (Seed Awards)
- Maximum award: $150,000
- Duration: 12-18 months
- Focus: Target validation, lead identification
- Eligible activities: In vitro studies, preliminary animal work, medicinal chemistry
Preclinical Development (Development Awards)
- Maximum award: $600,000
- Duration: 18-24 months
- Focus: Lead optimization, IND-enabling studies
- Eligible activities: Pharmacokinetics, toxicology, formulation development
Translation (Translation Awards)
- Maximum award: $1,000,000
- Duration: 24-36 months
- Focus: IND-enabling to Phase I
- Eligible activities: GMP manufacturing, regulatory support, Phase I trials
Applications undergo rigorous peer review:
- Letter of Intent: Initial screening for fit and quality
- Full Application: Detailed scientific and business plan
- External Review: Evaluation by scientific and business experts
- Investment Committee: Final review and funding decision
- Due Diligence: Detailed review of company and technology
The Diagnostics Accelerator represents a transformative investment in Alzheimer's diagnostics:
Blood-Based Biomarker Program
The ADDF has prioritized blood-based biomarkers as the most promising approach to early detection. Current projects include:
- Plasma Aβ42/40 ratio assays
- p-tau217 and p-tau181 measurements
- Neurofilament light chain (NfL) testing
- Multi-marker panels for improved accuracy
Digital Biomarker Program
Novel digital approaches being funded include:
- Voice analysis for cognitive assessment
- Smartphone-based cognitive testing
- Wearable device data for movement analysis
- Passive monitoring systems
CSF Biomarker Program
Cerebrospinal fluid biomarkers continue to be important:
- Novel CSF marker validation
- Less invasive collection methods
- Point-of-care CSF testing
The Diagnostics Accelerator works with:
- Leading diagnostic companies
- Academic medical centers
- Pharmaceutical companies
- Regulatory agencies
The ADDF-Harrington Scholar Program combines ADDF's scientific expertise with Harrington's drug development capabilities:
- Funding: Up to $400,000 over two years
- Mentorship: Access to team of drug development experts
- Business Development: Support for commercialization
- Network Access: Connections to pharmaceutical partners
- Scientific innovation
- Translational potential
- Team capabilities
- Institutional support
The Accelerating Medicines Partnership for Alzheimer's Disease represents a unique public-private collaboration:
- Academic Partners: Multiple universities and research centers
- Government Partners: NIH/NIA
- Pharmaceutical Partners: Major pharmaceutical companies
The partnership has created an unprecedented data resource:
- Genomics data from thousands of brains
- Transcriptomics across disease progression
- Proteomics and metabolomics data
- Clinical data integration
This open-science approach has accelerated target identification and biomarker development across the field.
The ADDF's FTD program addresses a significant unmet need:
- Genetic Forms: Support for research on GRN, MAPT, C9orf72 mutations
- Sporadic FTD: Understanding non-genetic forms
- Clinical Trials: Supporting intervention studies
- Biomarkers: Developing FTD-specific biomarkers
The FTD program works with:
- FTD advocacy organizations
- Academic FTD centers
- Pharmaceutical companies with FTD programs
The ADDF's investments have contributed to significant scientific advances:
- Novel Target Validation: Multiple new therapeutic targets validated through ADDF-funded research
- Biomarker Discovery: Discovery of novel diagnostic and prognostic biomarkers
- Clinical Trial Innovation: Development of novel trial designs and endpoints
- Technology Development: Advancement of drug delivery and formulation technologies
The ADDF has influenced the pharmaceutical industry:
- Portfolio Company Success: Multiple companies acquired or gone public
- Partner Engagement: Increased industry interest in non-amyloid approaches
- Pipeline Development: Multiple ADDF-supported programs in clinical development
- Risk Capital Mobilization: Attracted additional investment to the field
The ADDF has become a thought leader:
- Conference Leadership: Major presentations at scientific conferences
- Publication Influence: High-impact publications in top journals
- Policy Input: Advisory roles in national and international research planning
- Media Coverage: Regular coverage in scientific and popular media
¶ Revenue and Investment
The ADDF operates on a unique financial model:
- Individual Donors: Major gifts from individuals
- Foundation Grants: Support from other foundations
- Corporate Partners: Pharmaceutical and diagnostic companies
- Investment Returns: Returns from portfolio companies
The venture philanthropy model generates returns:
- Equity Appreciation: Value increases in portfolio companies
- Exit Events: IPOs and acquisitions generate returns
- Dividend Income: Some investments generate income
- Reinvestment: Returns are recycled into new investments
- Total Capital Invested: Hundreds of millions across portfolio
- Annual Grant-making: Significant annual expenditure on new awards
- Diagnostics Accelerator: $150 million committed over multiple years
- Administrative Efficiency: Low overhead maximizes research funding
¶ Governance and Operations
The ADDF is governed by:
- Board of Directors: Strategic oversight and fiduciary responsibility
- Scientific Advisory Board: Scientific direction and review
- Investment Committee: Investment decisions and portfolio management
The ADDF maintains:
- Lean Operations: Small team maximizes research funding
- Expertise: Staff with drug development and scientific expertise
- Network: Extensive network of collaborators and advisors
- Flexibility: Ability to move quickly on promising opportunities
The ADDF continues to evolve and expand its impact:
-
Precision Medicine: Developing therapies for specific subtypes of Alzheimer's
- Understanding heterogeneity in Alzheimer's pathogenesis
- Targeting specific molecular subtypes
- Personalized treatment approaches
-
Combination Therapies: Supporting approaches that target multiple mechanisms
- Combining novel mechanisms with traditional approaches
- Multi-target interventions
- Rational drug combinations
-
Prevention: Funding trials in pre-symptomatic populations
- Identifying at-risk individuals
- Early intervention strategies
- Lifestyle modification studies
-
Biomarker-Driven Trials: Using biomarkers for patient selection and endpoint measurement
- Surrogate endpoints for faster trials
- Patient stratification
- Treatment response monitoring
The ADDF is expanding into new areas:
- Expanded FTD Program: Increased focus on frontotemporal dementia
- Additional Diagnostic Modalities: Beyond blood and digital biomarkers
- International Partnerships: Expanded global collaboration
- New Funding Mechanisms: Alternative structures for larger programs
- Glial Biology: Understanding microglia and astrocytes in disease
- Metabolism: Brain metabolism and metabolic dysfunction
- Circadian Rhythms: Sleep and circadian contributions to neurodegeneration
- Multi-Omics: Integration of genomics, proteomics, and metabolomics